Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Dominik Lott"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 1, Pp 74-86 (2023)
Abstract The analysis aimed at identifying subject‐specific characteristics (covariates) influencing exposure to daridorexant and quantification of covariate effects to determine clinical relevance. Data from 13 phase I, two phase II, and two phase
Externí odkaz:
https://doaj.org/article/f582678a99fb4ed5980311f3421d8784
Autor:
Roxana Aldea, Hans Peter Grimm, Ronald Gieschke, Carsten Hofmann, Dominik Lott, Szofia Bullain, Paul Delmar, Gregory Klein, Marco Lyons, Fabrizio Piazza, Roxana O. Carare, Norman A. Mazer
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction Amyloid‐related imaging abnormalities with edema/effusion (ARIA‐E) are commonly observed with anti‐amyloid therapies in Alzheimer's disease. We developed a semi‐mechanistic, in silico model to understand the time course
Externí odkaz:
https://doaj.org/article/0b614bdc96e645a1b1ef006dde12af9c
Autor:
Beate Bittner, Dietmar Schwab, Agnes Portron, Dominik Lott, Frank Boess, Rémy Kohler, Jakub Wojtowicz, Carsten Hofmann
Publikováno v:
Monday, April 24.
Autor:
Norman A Mazer, Carsten Hofmann, Dominik Lott, Ronald Gieschke, Gregory Klein, Frank Boess, Hans Peter Grimm, Geoffrey A. Kerchner, Monika Baudler, Janice Smith, Scott Schobel, Rachelle S. Doody
Publikováno v:
Alzheimer's & Dementia. 18
Publikováno v:
CPT: pharmacometricssystems pharmacologyREFERENCES.
The analysis aimed at identifying subject-specific characteristics (covariates) influencing exposure to daridorexant and quantification of covariate effects to determine clinical relevance. Data from 13 phase I, two phase II, and two phase III studie
Publikováno v:
The Journal of Clinical Pharmacology. 61:82-89
Half-life is a standard result reported with analysis of pharmacokinetic data. Different definitions such as noncompartmental half-life, terminal half-life, effective half-life, and context-sensitive half-life can yield substantially different estima
Publikováno v:
Br J Clin Pharmacol
Aims Assessment of time to attain steady state as well as drug accumulation following long-term treatment with the selective sphingosine-1-phosphate 1 receptor modulator cenerimod and prediction of the incidence of low total lymphocyte (LY) counts. D
Publikováno v:
Clinical Pharmacology & Therapeutics. 103:1083-1092
Ponesimod is a selective sphingosine-1-phosphate-1 (S1P1) receptor modulator currently under investigation for the treatment of multiple sclerosis. S1P receptor modulators reduce heart rate following treatment initiation. This effect disappears with
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 6:477-485
Selexipag (Uptravi) is an oral selective IP prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH). The pivotal GRIPHON study was the largest clinical study ever conducted in PAH patients, providing long-ter
Autor:
Andreas Krause, Dominik Lott, Thorsten Lehr, Christian Alexander Seemayer, Daniel S. Strasser, Jasper Dingemanse
Publikováno v:
Pharmaceutical Research. 34:599-609
This analysis aimed at describing the effect of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod on lymphocyte subsets in peripheral blood. As the involvement of different lymphocyte subsets varies among different autoimmune disea